The initial qualification of our proprietary modular manufacturing platform (BioMod™) marks a turning point toward scalable, cost-effective biologics manufacturing in Africa — advancing health sovereignty and local production capacity.

"This is a foundational leap for Bio Usawa and for Africa," said Patrick Lukulay, Ph.D., Bio Usawa's Chief Operating Officer, about the milestone.

The BioMod™ platform is now en route to Rwanda, where it'll anchor the first manufacturing facility for monoclonal antibodies (mAbs) in the region.